Listen

Press releases

Receive e-mail alerts

Interne link ProQR to Present at EuroTIDES Conference
oktober 31, 2017 om 11:00 AM UTC
Interne link ProQR Announces Management Change and Key Promotions
oktober 26, 2017 om 11:00 AM UTC
Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
oktober 24, 2017 om 11:00 AM UTC
Interne link ProQR to Present at the Chardan Inaugural Gene Therapy Conference
oktober 06, 2017 om 11:00 AM UTC
Interne link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis
september 25, 2017 om 08:00 PM UTC
Interne link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology
september 21, 2017 om 11:05 AM UTC
Interne link ProQR to Present at Two Investor Conferences in September
september 21, 2017 om 11:00 AM UTC
Interne link ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences
september 19, 2017 om 11:00 AM UTC
Interne link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics
september 12, 2017 om 11:00 AM UTC
Interne link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
september 05, 2017 om 11:00 AM UTC
Interne link ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial
augustus 29, 2017 om 11:00 AM UTC
Interne link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong
augustus 28, 2017 om 11:00 AM UTC
Interne link ProQR Announces Results for the Second Quarter of 2017
augustus 16, 2017 om 11:00 AM UTC
Interne link ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA
juli 05, 2017 om 11:00 AM UTC
Interne link ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology
juni 15, 2017 om 11:04 AM UTC
Interne link ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference
juni 13, 2017 om 11:00 AM UTC
Interne link ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial
juni 08, 2017 om 01:03 PM UTC
Interne link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
mei 31, 2017 om 11:00 AM UTC
Interne link ProQR Announces Results for the First Quarter of 2017
mei 17, 2017 om 11:00 AM UTC
Interne link ProQR remembers co-founder Henri Termeer after his unexpected passing
mei 15, 2017 om 11:00 AM UTC
Interne link ProQR Announces R&D Day in New York on June 15
mei 09, 2017 om 11:00 AM UTC
Interne link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
mei 01, 2017 om 11:00 AM UTC
Interne link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
april 27, 2017 om 11:00 AM UTC
Interne link ProQR to Present at the Deutsche Bank Health Care Conference
april 20, 2017 om 11:00 AM UTC
Interne link ProQR Announces Annual Meeting of Shareholders
april 10, 2017 om 11:00 AM UTC

Press releases

Interne link ProQR to Present at EuroTIDES Conference

Interne link ProQR Announces Management Change and Key Promotions

Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference

Interne link ProQR to Present at the Chardan Inaugural Gene Therapy Conference

Interne link ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

Interne link ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology

Interne link ProQR to Present at Two Investor Conferences in September

Interne link ProQR Receives Orphan Drug Designation from FDA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa and will Present Data at two Scientific Conferences

Interne link ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics

Interne link ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Interne link ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial

Interne link ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong

Interne link ProQR Announces Results for the Second Quarter of 2017

Interne link ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA

Interne link ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology

Interne link ProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science Conference

Interne link ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial

Interne link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

Interne link ProQR Announces Results for the First Quarter of 2017

Interne link ProQR remembers co-founder Henri Termeer after his unexpected passing

Interne link ProQR Announces R&D Day in New York on June 15

Interne link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Interne link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

Interne link ProQR to Present at the Deutsche Bank Health Care Conference

Interne link ProQR Announces Annual Meeting of Shareholders